Development of the “Hamburg Best Practice Guidelines for ICV−Enzyme Replacement therapy (ERT) in CLN2 Disease” Based on 6 Years Treatment Experience in 48 Patients
February 5, 2021
Related Stories
No related posts.
You’re leaving the BioMarin website.
Links to sites outside of this website are provided as a resource to the viewer. BioMarin accepts no responsibility for the content of linked sites.
Please locate the 8-digit DIN number found on your product package or educational materials and enter it in the form below to access important safety information.
